Trial · NCT04435626
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | Finerenone (BAY94-8862) | 1083 | events | ||
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | Placebo | 1283 | events | ||
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | Finerenone (BAY94-8862) | 624 | Participants | ||
| Occurrence of the Composite Endpoint of Cardiovascular Death and Total (First and Recurrent) Heart Failure Events | Placebo | 719 | Participants | ||
| Occurrence of Total (First and Recurrent) Heart Failure Events | Finerenone (BAY94-8862) | 842 | events | ||
| Occurrence of Total (First and Recurrent) Heart Failure Events | Placebo | 1024 | events | ||
| Occurrence of Total (First and Recurrent) Heart Failure Events | Finerenone (BAY94-8862) | 479 | Participants | ||
| Occurrence of Total (First and Recurrent) Heart Failure Events | Placebo | 573 | Participants | ||
| Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) | Finerenone (BAY94-8862) | 7.99 | 95% Confidence Interval 7.37 to 8.62 | score on scale | |
| Change From Baseline in Total Symptom Score (TSS) of the Kansas City Cardiomyopathy Questionnaire (KCCQ) | Placebo | 6.43 | 95% Confidence Interval 5.79 to 7.07 | score on scale | |
| Proportion of Participants Who Showed Improvement in NHYA Class | Finerenone (BAY94-8862) | 0.179 | 95% Confidence Interval 0.163 to 0.195 | Estimated proportion | |
| Proportion of Participants Who Showed Improvement in NHYA Class | Placebo | 0.178 | 95% Confidence Interval 0.162 to 0.194 | Estimated proportion | |
| First Occurrence of Renal Composite Events | Finerenone (BAY94-8862) | 75 | Participants | ||
| First Occurrence of Renal Composite Events | Placebo | 55 | Participants | ||
| Occurence of All-cause Mortality (Full Analysis Set) | Finerenone (BAY94-8862) | 491 | Participants | ||
| Occurence of All-cause Mortality (Full Analysis Set) | Placebo | 522 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04435626/results